Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

87.58 +0.53 (+0.61%)

Streaming Delayed Price Updated: 12:20 PM EDT, Sep 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	364,035
Open	86.71
Bid (Size)	87.49 (100)
Ask (Size)	87.68 (400)
Prev. Close	87.05
Today's Range	85.78 - 87.90
52wk Range	14.51 - 110.17
Shares Outstanding	101,192,921
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Wednesday's pre-market session: top gainers and losers ↗

August 26, 2026

Via Chartmill

What's going on in today's after hours session ↗

August 25, 2026

Via Chartmill

Performance

YTD	+186.4%	+186.4%
1 Month	-7.7%	-7.7%
3 Month	+19.1%	+19.1%
6 Month	+113.6%	+113.6%
1 Year	+426.7%	+426.7%

More News

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

August 25, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

August 10, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know ↗

August 06, 2026

Via The Motley Fool

A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know ↗

August 06, 2026

Via The Motley Fool

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 04, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

June 15, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

June 03, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 26, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Via The Motley Fool

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗

May 17, 2026

Via The Motley Fool

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗

May 17, 2026

Via The Motley Fool

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗

May 17, 2026

Via The Motley Fool

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 05, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

April 16, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

April 14, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

April 13, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

These stocks are gapping in today's session ↗

April 13, 2026

Via Chartmill

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

April 13, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

April 10, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears ↗

April 08, 2026

Via The Motley Fool

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

March 16, 2026

From Spyre Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Spyre Therapeutics, Inc. - Common Stock publicly traded?

Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?

Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?

The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market

What is the current price of Spyre Therapeutics, Inc. - Common Stock?

The current price of Spyre Therapeutics, Inc. - Common Stock is 87.58

When was Spyre Therapeutics, Inc. - Common Stock last traded?

The last trade of Spyre Therapeutics, Inc. - Common Stock was at 09/03/26 12:20 PM ET

What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?

The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 8.86B

How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?

Spyre Therapeutics, Inc. - Common Stock has 9B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.